A Pharmaceutical Quality System (PQS) is an integrated system of organisational arrangements, processes, procedures and resources designed to ensure that medicinal products consistently meet the quality requirements appropriate to their intended use. It provides the framework for managing pharmaceutical quality throughout the product lifecycle, from development and technology transfer to commercial manufacturing and product discontinuation.
Definition and Regulatory Context
The Pharmaceutical Quality System is a central concept in modern pharmaceutical quality management. It brings together the organisational structure, responsibilities, procedures, processes and resources required to maintain and continuously improve product quality.
Unlike a system focused exclusively on quality control or final product testing, a PQS operates across the entire pharmaceutical manufacturing process. It incorporates Good Manufacturing Practice (GMP), quality risk management, knowledge management, change control, deviation management, corrective and preventive actions (CAPA), and management review.
The internationally harmonised ICH Q10 guideline provides the principal model for a pharmaceutical quality system. Regional GMP frameworks, including those of the European Union and the Eurasian Economic Union, establish corresponding requirements for manufacturers.
Official Definitions and Regulatory Sources
1. International Council for Harmonisation (ICH) — Pharmaceutical Quality System
Source: ICH Q10 — Pharmaceutical Quality System
Reference: Sections 1.1–1.2, Introduction and Scope
ICH Q10 does not establish a standalone dictionary definition of PQS. Instead, it describes a harmonised model for an effective pharmaceutical quality management system, referred to as the Pharmaceutical Quality System.
The guideline explains that the ICH Q10 model is based on ISO quality concepts, incorporates applicable GMP requirements and complements ICH Q8 (Pharmaceutical Development) and ICH Q9 (Quality Risk Management).
The model applies to systems supporting the development and manufacture of pharmaceutical drug substances and drug products, including biotechnology and biological products, throughout the product lifecycle.
ICH Q10 identifies four main elements of the pharmaceutical quality system:
- Process performance and product quality monitoring system;
- Corrective action and preventive action (CAPA) system;
- Change management system;
- Management review of process performance and product quality.
Official source: ICH Q10 — Pharmaceutical Quality System
2. Eurasian Economic Union — Pharmaceutical Quality System
Source: Good Manufacturing Practice Rules of the Eurasian Economic Union
Reference: Chapter 1, Section 1, Paragraphs 1.22–1.27; Decision of the Council of the Eurasian Economic Commission No. 77 of 3 November 2016, as amended
The EAEU GMP Rules define a Pharmaceutical Quality System as:
“The totality of measures taken to ensure that medicinal products possess the quality required for their intended use.”
The Rules further require the system to take account of the size of the company and the complexity of its activities. Senior management must actively participate in ensuring the effectiveness of the pharmaceutical quality system.
The requirements also address personnel competence, premises and equipment, documentation, manufacturing processes, independent quality control, change management, deviation investigation, CAPA, traceability and continuous evaluation of system effectiveness.
Official source: Eurasian Economic Commission — Legal Acts
3. European Union — Pharmaceutical Quality System
Source: Commission Directive (EU) 2017/1572
Reference: Article 2(2)
EU legislation defines a Pharmaceutical Quality System as:
“The total sum of the organised arrangements made with the objective of ensuring that medicinal products are of the quality required for their intended use.”
This definition establishes the organisational and quality assurance basis of the system. The corresponding GMP requirements are set out in EudraLex Volume 4, particularly Chapter 1, “Pharmaceutical Quality System”.
EU GMP Chapter 1 describes the responsibilities of senior management, the role of the quality system in ensuring product quality, and the application of quality risk management and continuous improvement throughout the product lifecycle.
Official sources:
- Commission Directive (EU) 2017/1572 — EUR-Lex
- EudraLex Volume 4 — EU Guidelines for Good Manufacturing Practice
4. United States — Pharmaceutical Quality System
Source: US Food and Drug Administration (FDA), Guidance for Industry Q10 — Pharmaceutical Quality System
Reference: Guidance document issued in April 2009
The FDA recognises the ICH Q10 model as an internationally harmonised framework for an effective quality management system in the pharmaceutical industry.
The FDA guidance states that the term Pharmaceutical Quality System refers to the ICH Q10 model. It is intended to assist pharmaceutical manufacturers in developing and maintaining an effective quality system throughout the product lifecycle.
The guidance represents the FDA’s current thinking on the subject and does not independently create legally binding requirements. Applicable statutory and regulatory GMP requirements remain in force.
Official source: FDA — Q10 Pharmaceutical Quality System
5. World Health Organization — Quality System and GMP
Source: WHO Prequalification Programme Glossary and WHO Good Manufacturing Practices guidance
WHO uses the broader term Quality System in its glossary. It defines this as an appropriate infrastructure encompassing the organisational structure, procedures, processes and resources, together with systematic actions necessary to provide adequate confidence that a product or service will satisfy specified quality requirements.
WHO also describes GMP as part of a quality management system that ensures products are consistently produced and controlled according to quality standards appropriate to their intended use and marketing authorisation.
These WHO descriptions provide relevant international quality management context, although they should not be presented as a standalone WHO definition of the term Pharmaceutical Quality System.
Official sources:
Related Terminology in Pharmaceutical Quality Management
Several related terms are used in pharmaceutical regulation and quality management. They describe connected concepts but should not automatically be treated as interchangeable.
- Quality Management System (QMS): A general management framework for establishing quality policies and objectives and achieving them through organisational structures, processes and resources. PQS is the pharmaceutical industry-specific application of this broader concept.
- Good Manufacturing Practice (GMP): The part of quality assurance that ensures medicinal products are consistently produced and controlled in accordance with appropriate quality standards. GMP is an integral part of the PQS.
- Quality Assurance (QA): The wider range of organised arrangements intended to ensure that products have the quality required for their intended use. It encompasses GMP and other quality-related activities.
- Quality Control (QC): The part of GMP concerned with sampling, specifications, testing, documentation and release procedures to ensure that materials and products meet established quality requirements.
- Quality Risk Management (QRM): A systematic process for the assessment, control, communication and review of risks to product quality throughout the product lifecycle.
- Corrective and Preventive Actions (CAPA): A system for investigating deviations and quality problems, identifying their causes, implementing corrective measures and preventing recurrence.
Regulatory Significance
An effective Pharmaceutical Quality System is essential for ensuring consistent product quality and maintaining compliance with applicable GMP requirements. It provides the framework through which manufacturers identify, control and continuously improve processes that may affect the quality of medicinal products.
Key areas covered by a PQS include:
- Management responsibility: Senior management establishes the quality policy, allocates resources and oversees system effectiveness.
- Quality risk management: Risks to product quality are identified, assessed and controlled using a systematic and scientifically justified approach.
- Deviation and CAPA management: Deviations, non-conformities and quality complaints are investigated, with appropriate corrective and preventive actions implemented.
- Change management: Proposed changes to materials, processes, equipment, facilities and documentation are assessed and approved before implementation where required.
- Process and product quality monitoring: Manufacturing performance and product quality data are reviewed to identify trends and opportunities for improvement.
- Management review: The effectiveness of the quality system is periodically evaluated, and appropriate improvements are identified.
- Lifecycle management: Quality oversight extends across pharmaceutical development, technology transfer, commercial manufacturing and product discontinuation.
For regulatory inspections, the PQS is a key area of assessment. Inspectors evaluate not only whether documented procedures exist, but also whether the system is effectively implemented, deviations are properly investigated and quality risks are adequately controlled.
Editorial Note
The term Pharmaceutical Quality System is used in ICH Q10 and regional GMP frameworks. The EAEU and EU GMP rules provide explicit legal definitions, while ICH Q10 describes an internationally harmonised model for the system’s structure and operation. WHO materials use related broader terminology, including Quality System and Quality Management System.
For regulatory interpretation, the applicable legislation and GMP requirements in the relevant jurisdiction take precedence. ICH Q10 should be read as a harmonised guideline model rather than a substitute for binding national or regional GMP legislation.
